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Background: Oral verruciform xanthoma (OVX) is a rare lesion. The purpose of the present study is to describe 
the clinical features of 13 OVXs and review all cases reported in the English literature.
Material and Methods: Thirteen cases of OVX diagnosed during a 47-year period were retrospectively collected. 
The patients’ gender and age, as well as the main clinical features of the lesions were retrieved from the biopsy 
request forms. Pubmed®, Scopus® and Google ScholarTM electronic databases were searched with the key word 
“verruciform xanthoma”. Only cases of histologically confirmed OVX were included in the study. 
Results: The 13 OVXs represented approximately 0.04% of 35,617 biopsies accessioned during the study period. 
They affected 13 patients, 8 males and 5 females with a mean age of 48.8±14 years. They mainly appeared as 
asymptomatic granular nodules or plaques, with elastic or normal consistency and white color, in the gingiva or 
hard palate. Literature review yielded 416 cases of OVX. With the addition of cases of the present study, 429 cases 
of OVX have been presented in the English literature. OVX has a slight male predominance with a male to female 
ratio of 1.4:1 and the majority of patients are in the 5th to 7th decade of life. Clinically, OVX mainly presents as 
an asymptomatic, single, papillary or granular plaque or nodule, with elastic or soft consistency and white, red or 
pink color. It measures approximately 1cm and is most commonly located on the gingiva, tongue, hard palate or 
buccal mucosa. The treatment of choice is surgical excision with little rates of recurrence.
Conclusions: Verruciform xanthoma is a rare lesion most often encountered on the ginigival mucosa. As its clini-
cal presentation is not pathognomonic, it should be included in the differential diagnosis of verrucous or papillary 
lesions.
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Introduction
Verrucifrom xanthoma is a rare benign lesion of un-
known pathogenesis, first described in the oral cavity 
by Shafer in 1971 (1). Similar lesions have been report-
ed in the anogenital area (2), i.e. the penis, the scrotum 
and vulva (3), as well as in the skin, the latter usually 
in association with chronic inflammatory skin diseases 
such as dystrophic epidermolysis bullosa and cutane-
ous discoid lupus erythematous, chronic or congenital 
lymphoedema, graft versus host disease, and congenital 
epidermal nevi (2).
Oral verruciform xanthoma (OVX) manifests as an as-
ymptomatic, solitary, sharply demarcated and slightly 
raised plaque usually located on the gingiva, with a pap-
illary, granular or verrucous surface, and red or pink 
color (4). It shows a slight male predilection and most 
patients are in the 5th to 7th decade of life (4). Micro-
scopic examination discloses a papillary or verrucous 
proliferation of hyperparakeratotic squamous epitheli-
um with a characteristic orange hue, and aggregation of 
“foamy or xanthoma cells” within the connective tissue 
(4-6). The ret pegs are elongated with uniform depth 
(4,7) and deep, keratin-filled clefts may be noticed be-
tween the epithelial projections (4). Exocytosis of neu-
trophils in the parakeratin layer and infiltration of lym-
phocytes and plasma cells in the connective tissue may 
also be seen (7). The xanthoma cells are macrophages of 
varying size with eccentrically placed nuclei (4,8); they 
are mostly confined to the connective tissue papillae, 
but may extend beyond the level of the rete ridges (7,8). 
They may replace all connective tissue elements in the 
papillae or be sparsely present (4,7).
We report the clinical features of 13 new cases of OVX 
and review the pertinent English literature with regard 
to the clinical and demographic features, etiology, 
pathogenesis and treatment.
Material and Methods
The study was approved by the Research Ethics 
Committee of Athens Dental School (code number 
349/08.11.2017). 
Fourteen cases of OVX were retrospectively retrieved 
from the files of the Department of Oral Medicine and 
Pathology from January 1971 to July 2017. The diag-
nosis in each case was reconfirmed by studying repre-
sentative hematoxylin and eosin stained tissue sections. 
The age and gender of the patients, as well as location 
and main clinical features of the lesions were collected 
from the biopsy request forms and tabulated.
For the literature review, Pubmed®, Scopus® and 
Google ScholarTM electronic databases were searched 
using the keyword “verruciform xanthoma” up to July 
15, 2017. All cases of microscopically confirmed VX 
located in the oral mucosa that were published in the 
English literature were retrieved. The references of all 
retrieved publications were manually searched for addi-
tional cases. Multiple lesions or recurrences were con-
sidered as OVX only when they were microscopically 
confirmed. The age and gender of the patients, location 
and main clinical features of the lesions, as well as fol-
low-up data were collected and tabulated.
Results 
Out of 35,617 biopsies accessioned during the study pe-
riod, 14 cases of solitary OVX were found, representing 
0.04% of total number. As one of those cases had been 
previously described in the English literature (9), the 
clinical features of the 13 new cases are tabulated in Ta-
ble 1. Eight patients (61.5%) were males and 5 (38.5%) 
were females, the male to female ratio being 1.6:1. Age 
was reported in eleven patients and ranged from 28 to 
73 years (mean age 48.8±14 years, median age 48 years). 
The mean age of the males (mean age 42.1±11.6 years, 
median 38 years) was younger than that of the females 
(mean age 60.5±9.4 years, median 60.5 years), the dif-
ference being statistically significant (p<0.05). Most 
lesions were clinically described as asymptomatic nod-
ules (6 cases, 46.2%), plaques (5 cases, 38.5%) or ul-
cers (2 cases, 15.4%), of white (8 cases, 72.7%), pink (2 
cases, 18.2%), or red (1 case, 9.1%) color. Their surface 
was granular (6 cases, 54.5%), rough (2 cases, 18.2%), 
papillary (2 cases, 18.2%) or verrucous (1 case, 9.1%). 
Consistency was described as elastic (5 cases, 62.5%), 
normal (2 cases, 25%) or soft (1 case, 12.5%). Size was 
reported in 9 cases and approximately half of them 
measured less than 1cm in largest dimension (range 
0.3-2.5cm, mean 1±0.7cm, median 0.7cm). Most lesions 
were located on the gingiva (5 cases, 38.5%), followed 
by the hard palate (3 cases, 23.1%), lateral border of the 
tongue (2 cases, 15.4%), lower lip (2 cases, 15.4%) and 
alveolar mucosa (1 case, 7.7%).
The literature review yielded 74 publication with a total 
number of 416 cases of OVX (1,4,9-73). With the addi-
tion of the 13 new cases of the present study, the total 
number of OVXs reported in the English literature is 
429. There was a slight male predominance with 233 
cases (58%) occurring in male patients and 169 cases 
(42%) in females (male to female ratio 1.4:1). Age ranged 
from 2.5 to 89 years, with the majority of patients being 
in the 5th to 7th decade of life (mean age 51 years). The 
mean age of males (47.6 years) was younger than that 
of females (55.8 years), the difference being statistically 
significant (p<0.05). Male to female ratio before the age 
of 50 years was 2.1:1, but after the age of 50 years is ap-
proximately 1:1. Age distribution according to gender 
is shown in Fig 1. OVX usually manifested as a single 
lesion (341 cases, 98.6%), but in 5 cases (4,24,42,55,71) 
multiple lesions were seen. There were, also, 2 cases 
with multiple lesions (39,72), but biopsy was performed 
in only one of them. In one case (55) 4 OVXs were 




Gender Age* Site Size** Clinical 
Description
Consistency Surface Color Duration 
***
Symptoms
1 M 36 MaAG 0.5 Nodule Elastic Granular Pink 36 No
2 M 38 MxPG 1.5 Ulcer - Papillary White 0,5 -
3 M 36 MaPG 0.3 Nodule Elastic Rough White 12 No
4 F - LLM 0.7 Nodule Elastic Granular White 12 No
5 M - LLM 1 Nodule Elastic Granular White - No
6 M 63 MxAM 0.5 Nodule Soft Granular - - No
7 F 48 HP - Plaque - - - - No
8 F 56 LT - Nodule Elastic Veruccous Pink 3 -
9 M 28 MxPG 1.5 Ulcer - Rough White 2 No
10 F 65 HP - Plaque Normal - White 12 No
11 M 38 MxAG - Plaque - Granular White 0,5 No
12 F 73 HP 0.5 Plaque Normal Granular Red 0,75 No
13 M 56 LT 2.5 Plaque - Papillary White - No
Table 1: Demographics and clinical characteristics of 13 cases of oral verruciform xanthoma.
Fig. 1: Age of patients related to gender and decade of life.
*Years, ** Maximum diameter in cm, *** Months.
Abbreviations: M, male; F, female; MaAG, mandibular anterior gingiva; MxAG, maxillary anterior gingiva; MxPG, maxillary posterior gin-
giva; MaPG, mandibular posterior gingiva; LLM, lower lip mucosa; MxAM, maxillary alveolar mucosa; HP, hard palate; LT, lateral tongue.
present and in another 4 cases 2 lesions were detected 
(4,24,42,71). In 2 cases, OVX manifested concurrently 
with extraoral lesions (25,66), while one case with mul-
tifocal lesions was described as “disseminated” verru-
cifom xanthoma (74). The majority of OVXs were lo-
cated on the gingiva (182 cases, 45.3%), followed by the 
tongue (53 cases, 13.2%), hard palate (51 cases, 12.7%), 
buccal mucosa (37 cases, 9.2%), alveolar mucosa (25 
Med Oral Patol Oral Cir Bucal. 2018 Jul 1;23 (4):e429-35.                                                                                                                                                                           Oral verruciform xanthoma
e432
cases, 6.2%), floor of the mouth (15 cases, 3.7%), lips 
(15 cases, 3.7%), soft palate (9 cases, 2.2%), maxillary 
buccal vestibule (4 cases, 1%), vermillion border of 
the lower lip (3 cases, 0.7%), palatal junction (3 cases, 
0.7%) and lower mucobuccal fold (2 cases, 0.5%). Single 
cases were also seen on the retromolar pad (0.3%), man-
dibular posterior gingiva with extension to the buccal 
mucosa (0.3%) and maxillary anterior gingiva extend-
ing to the upper lip (0.3%). Clinically, in the majority 
of cases, OVX presented as a plaque (19 cases, 38%), 
nodule (11 cases, 22%) or mass (6 cases, 12%), of white 
(22 cases, 29%), red (15 cases, 19.7%), pink (14 cases, 
18.4%) or yellow (10 cases, 13.2%) color, with elastic 
(6 cases, 40%) or soft (6 cases, 40%), consistency. The 
surface was papillary (35 cases, 38.5%), granular (22 
cases, 24.2%), or verrucous (17 cases, 18.7%). Most le-
sions measured approximately 1cm in major diameter 
(mean size 1±0.7cm, median size 1cm). In 95.7% of the 
cases no symptoms were present, justifying the long du-
ration of 12.8±19.7 months (range 2 weeks-12 years, me-
dian duration 6 months) before diagnosis. In one case 
(11) a barely discernible radiolucency could be noticed 
upon radiographic examination. The follow up period 
ranged from 2 months – 18 years (mean follow-up time 
8.9±8 years, median follow-up time 3 years) and 6 cases 
recurred (12%). In 99.1% of the cases, surgical excision 
was performed, whereas in 2 cases diagnosis was estab-
lished after incisional biopsy followed by total excision 
with electro-cautery knife (28) or carbon dioxide laser 
(49). In one case (66) imiquimod was locally applied af-
ter surgical excision.
Cases of OVX was described in patients with oral li-
chen planus (10 cases) (7,15,16,32,35,41,48,65); graft 
versus host disease (7 cases) (4,29,46); bone marrow 
transplantation (5 cases) (49,53,66, cases 4 and 5 of the 
present study); oral squamous cell carcinoma (4 cases) 
(15,26,41,65); leukoplakia (1 case) (7); amyloidosis (1 
case)  (7); in patients under chemotherapy and radio-
therapy for lymphoma (2 cases) (8); oral pemphigus 
vulgaris (1 case)  (19), oral discoid lupus erythematous 
(1 case)  (37), submucosal fibrosis (1 case)  (41), neuro-
fibromatosis (1 case)  (47) and paracoccioidiomycosis 
(1 case)  (65). In three cases, OVX occurred simulta-
neously with osteoma (8), carcinoma in situ (26) and 
warthy dyskeratoma (30).
Discussion
OVX is a rare lesion, as Shafer (1) reported 15 cases 
(0,045%) among 33,000 biopsies during a 23 year pe-
riod and Jones and Franklin (75) 9 cases (0.02%) among 
44,007 biopsies during a 30 year period. The 14 cases 
retrieved from the files of our Department represent 
0.04% of 35.617 biopsies diagnosed during a 47 year pe-
riod. In their review Philipsen et al. (4) found 199 cases 
of OVX in the English literature and 83 cases in the Jap-
anese literature. Since this review 134 cases have been 
published in the English literature that in addition to the 
13 new cases found in our files raise the total number 
of OVX to 429 cases. The more common occurrence of 
OVX in males than females and in middle-aged patients 
(4) was confirmed in the present study. The clear male 
predominance of the lesion in patients younger than 50 
years of age, as well as their tendency to occur almost a 
decade earlier in males compared to females cannot be 
explained. The gingiva is the most commonly involved 
oral site, followed by the tongue, hard palate, and buccal 
mucosa (4).
The clinical differential diagnosis includes other ver-
rucous lesions, such as verrucous leukoplakia, verru-
cous carcinoma, squamous papilloma, verruca vulgaris, 
condyloma acuminatum and squamous cell carcinoma 
(46,63). 
Diagnosis requires microscopic examination. Now-
parast et al. (17) have described three histologic sub-
types of OVX that do not correlate with clinical or prog-
nostic parameters, and most probably represent various 
stages of the disease progression (25). 
Immunohistochemically, parakeratin is negative for 
cytokeratin (CK) 14, in contrast to normal oral epithe-
lium and Syndecan 1/CD138 shows granular positivity 
compared to normal oral mucosa, where a membra-
nous pattern is seen (65). The foam cells are positive 
for CD68 and negative for S-100, positive for PAS and 
PAS-diastase (6, 8) and some of them may represent 
transformed fibroblasts (7). 
The pathogenesis of OVX is unknown. Unlike skin xan-
thomas no disturbance of lipid metabolism is reported, 
with the exception of one case (25) in a girl with an 
undefined systemic lipid disorder who developed a ver-
ruciform xanthoma on the tongue and in other parts 
of her body. A missense mutation in exon 6 of the 
3β-hydroxysteroid dehydrogenase (NSDHL) gene that 
plays an important role in cholesterol biosynthesis was 
found in 22% of cutaneous xanthomas, but this mutation 
has not been examined in OVX (76). As in cutaneous 
lesions (2), OVX is not related to HPV (25,33,38). Oc-
currence of most OVX on the masticatory mucosa lead 
to the hypothesis that a “local irritant”, such as trauma 
or inflammation, may cause epithelial degeneration and 
that the degenerated epithelium forms lipids scavenged 
by macrophages (12,13). However, this theory does not 
explain the occurrence of OVX in sites where trauma 
is not common, such as the soft palate or floor of the 
mouth (4), the lack of degenerative epithelial cells on 
microscopic examination (8,9) and the persistence of 
foamy cells in the connective tissue (5). Some authors 
consider the epithelial changes as secondary to the pres-
ence of foamy cells (17,25) or “illusionary” (8) due to 
the upward pushing effect from the macrophages. 
Accumulation of T lymphocytes, decreased number of 
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Langerhans cells (8) and active antigen presentation 
in the epithelium of OVX, especially at the site of in-
tense inflammation (33), suggest a local immunologic 
reaction (5). Accumulation of an inflammatory infil-
trate predominated by T lymphocytes to an unknown 
antigen may act as a chemoattractant to macrophages 
that through the expression of epithelial adhesion mol-
ecules persist in the lesion (5). According to Ide et al. 
(7), periodontopathic pathogens, tobacco, mechanical 
stimuli, alcohol, foodstuff sensitizing or allergic agents 
or dental materials and drugs, alter keratinocytes caus-
ing chronic epithelial damage and trigger inflammation, 
with the predominance of T lymphocytes. T lympho-
cytes in turn stimulate keratinocytes to release cyto-
kines and chemokines, thus attracting neutrophils (by 
IL-8 of the upper spinous keratinocytes) and additional 
T cells thus perpetuating T cell infiltration. T lympho-
cytes activate MCP-1 in the basal layer cells, which is 
a monocyte/macrophage cells attractor, thus attracting 
macrophages that express CCR2, the receptor of MCP-
1. Macrophages trap and internalize lipids released 
by degenerative keratinocytes, thus becoming foamy. 
Consequently, macrophages oxidize lipids causing self 
induced-toxicity and eventually necrosis. The inflam-
matory response to necrosis attracts new macrophages, 
thus perpetuating their presence in OVX (7). Finally 
Shahrabi Farahani et al. (46) proposed that disorders 
which lead to basal cells damage such as lichen planus, 
GVHD, pemphigus vulgaris and epidermolysis bullosa 
may also trigger the formation of OVX. 
OVX has good prognosis. Only 6 cases with recurrence 
after surgical excision (12%) (mean time of recurrence 
2.8±1.5 years) were recorded (17,22,33,7,47,57). This 
underlines the necessity for a follow-up. No case of ma-
lignant transformation has been reported. In one case 
squamous cell carcinoma developed in the area where 
an OVX was present four years earlier, but this was con-
sidered coincidental (6). 
Conclusions
Verruciform xanthoma is a rare lesion most often en-
countered on the ginigival mucosa. As its clinical pre-
sentation is not pathognomonic, it should be included 
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